Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding, Contraceptive Continuation, and Depression

• Status: Completed
• Trial end date: 2017-10-16
• Target enrollment: 0
• Participant gender: Female

Summary

The investigators plan to enroll 184 women who are planning to breastfeed and use DMPA after delivery to find out whether the timing of postpartum administration of DMPA (prior to hospital discharge or 4-6 weeks after delivery) affects the duration or exclusivity of breastfeeding among women who plan to breastfeed their infants.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Beatrice Chen; University of Pittsburgh
• Collaborator: Society of Family Planning
• Treatments: Contraceptive Agents; Medroxyprogesterone; Medroxyprogesterone Acetate

Criteria

Inclusion Criteria:

• Age > 18 years old and > 24 0/7 weeks pregnant at time of enrollment

• Planning to deliver at Magee-Womens Hospital and to breastfeed

• Plans to use DMPA for postpartum contraception for at least 6 months

• Willing and able to provide informed consent in English and to comply with study protocol

Exclusion Criteria:

• Intolerance of irregular vaginal bleeding

• Severe coagulation disorder

• Severe liver disease (LFTs >2x upper limits of normal at time of randomization)

• Contraindications to breastfeeding: maternal HIV infection; active herpes simplex with breast lesions; active varicella; active, untreated tuberculosis; antineoplastic, thyrotoxic, or immunosuppressive medications; concern that the infant may have galactosemia

• History of breast cancer, reduction or augmentation surgery

• History of severe clinical depression

• Multiple gestation